Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss

Table 2 Determination of factors related to virological relapse in patients with hepatitis B e antigen loss

	Univariate			Multivariate
	HR	95%CI	P values	HR	95%CI	P values
Age at cessation	1.021	0.987-1.056	0.235
Gender	0.783	0.405-1.515	0.468
Pretreatment ALT	0.999	0.998-1.001	0.451
Pretreatment AST	1.000	0.997-1.002	0.716
Pretreatment HBV DNA (log10 copies/mL)	1.391	0.942-2.054	0.097	1.256	0.816-1.933	0.300
Total treatment duration	1.001	0.989-1.013	0.826
HBV DNA negativity last time	1.001	0.988-1.013	0.915
Consolidation periods (≥ 24 mo vs < 24 mo)	0.469	0.247-0.891	0.021	0.506	0.262-0.978	0.043
HBsAg at cessation (≥ 100 IU/mL vs < 100 IU/mL)	15.515	2.119-113.575	0.007	14.869	2.027-109.084	0.008

HR: Hazard ratio; HBeAg: Hepatitis B e antigen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen.